A novel synthetic small molecule YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway

Fujun Dai a, b, #, Yihua Chen a, #, Li Huang a, Jinhua Wang a, Tao Zhang a, Jingjie Li a, Weiguang Tong a, Mingyao Liu a, c, Zhengfang Yi a, *

a Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
b The Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, China
c Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, TX, USA

Received: June 4, 2014; Accepted: August 29, 2014

Abstract

Cell migration and invasion are key processes in the metastasis of cancer, and suppression of these steps is a promising strategy for cancer therapeutics. The aim of this study was to explore small molecules for treating colorectal cancer (CRC) and to investigate their anti-metastatic mechanisms. In this study, six CRC cell lines were used. We showed that YH-306 significantly inhibited the migration and invasion of CRC cells in a dose-dependent manner. In addition, YH-306 inhibited cell adhesion and protrusion formation of HCT116 and HT-29 CRC cells. Moreover, YH-306 potently suppressed uninhibited proliferation in all six CRC cell lines tested and induced cell apoptosis in four cell lines. Furthermore, YH-306 inhibited CRC colonization in vitro and suppressed CRC growth in a xenograft mouse model, as well as hepatic/pulmonary metastasis in vivo. YH-306 suppressed the activation of focal adhesion kinase (FAK), c-Src, paxillin, and phosphatidylinositol 3-kinases (PI3K), Rac1 and the expression of matrix metalloproteases (MMP) 2 and MMP9. Meanwhile, YH-306 also inhibited actin-related protein (Arp2/3) complex-mediated actin polymerization. Taken together, YH-306 is a candidate drug in preventing growth and metastasis of CRC by modulating FAK signalling pathway.

Keywords: small molecule ● colorectal tumour ● metastasis ● FAK pathway

Introduction

Although screening, surgical resection and adjuvant therapy have improved the outcome for patients with colorectal cancer (CRC), CRC is still the third-leading cause of cancer-related deaths [1]. More than 140,000 new cases of CRC were estimated and more than 50,000 individuals will die from CRC during 2013 in the United States [2]. To address this conundrum, many studies focused on research for new therapies to target metastatic progression, as metastasis from the primary site of tumour growth to distant organs was the leading cause of cancer-related mortality [3].

Cancer metastasis involves a series of processes, including cell adhesion, spreading, migration, invasion and colonization in the new sites [4]. These processes are regulated by a variety of proteins, including cellular adhesion molecules, chemokines and their receptors, MMPs, other metastasis proteins and their downstream signalling pathways [5]. The adhesion of cells onto specific extracellular matrix (ECM) components induces the formation of focal adhesions, followed by the recruitment of cytoplasmic proteins, such as focal adhesion kinase (FAK), c-Src, paxillin, and phosphatidylinositol 3-kinases (PI3K), Rac1 and the expression of matrix metalloproteases (MMP) 2 and MMP9. Meanwhile, YH-306 also inhibited actin-related protein (Arp2/3) complex-mediated actin polymerization. Taken together, YH-306 is a candidate drug in preventing growth and metastasis of CRC by modulating FAK signalling pathway.
dynamics leading to the formation of cell protrusions [10]. During cell migration, the actin-related protein 2/3 complex drives the polymerization of actin filaments to direct cell protrusion, influencing cell migration and invasion [11].

To explore potential drug candidates against CRC metastasis, we screened one type of novel aryl tetrahydro-β-carboline derivatives for their inhibition efficacy towards CRC cell phenotypic assays, and found that YH-306 showed a significant inhibitory effect on the progression and development of CRC. In vitro, YH-306 significantly inhibited CRC cell migration, invasion, proliferation and colonization, and induced CRC cell apoptosis. In vivo, YH-306 depressed CRC growth and suppressed hepatic/pulmonary metastasis. Finally, we found that YH-306 blocked the activation of FAK and FAK-related signalling pathway, leading to the suppression of CRC growth and metastasis.

Materials and methods

Reagents, cell and animals

The antibodies used in this study were anti-Arp3; C-myc, Bax, Bcl-xl, Cleaved Caspase3, FAK, Phos-FAK, Phos-Pi3K, MMP2, MMP9, tissue inhibitor of metalloproteinases 1 (TIMP1), Paxillin, Phos-paxillin, Erk, Phos-Erk (Cell Signaling Technology), c-Src, Phos-c-Src (Santa Cruz Biotechnology) and Rac1 (Millipore). DAPI was purchased from Sigma-Aldrich. Phalloidin was provided by Invitrogen. All of the media were obtained from Gibco. All CRC cell lines were obtained from the American Type Culture Collection (ATCC). Medium was supplemented with 10% FBS, penicillin (100 units/ml) and streptomycin (100 units/ml). BALB/c mice and nude mice were from the National Rodent Laboratory Animal Resources, Shanghai Branch of China. All animal experimental protocols were approved by the Animal Investigation Committee of the Institute of Biomedical Sciences, East China Normal University.

Chemical synthesis of compound YH-306

As previous report [12, 13], compound YH-306 (Fig. 1A) was synthesized by our laboratory with greater than 98% purity. To a solution of 4-hydroxyphenylacetic acid (152 mg, 1.0 mmol) in anhydrous N,N-dimethylformamide (5.0 ml) was added 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (249 mg, 1.3 mmol) and 1-hydroxy-benzotriazole (149 mg, 1.1 mmol) at 0°C, the reaction mixture was stirred for 10–15 min., then 1,3,4,9-tetrahydro-β-carboline (172 mg, 1.0 mmol) was added. The mixture was stirred for another 3 hrs at room temperature and diluted with H2O and extracted with ethyl acetate (3 × 60 ml). The combined organic phase was dried over anhydrous sodium sulphate, then concentrated in vacuo and the crude product was chromatographed over silica gel to give 199 mg (65% yield) of compound YH-306.

Migration and invasion assays

For CRC cells, the migration and invasion assay was performed as previously reported [14]. After overnight starvation, the cells were scratched with a pipette tip followed by the addition of YH-306. Images were taken after 16 hrs, and migrated cells were counted. The migration and invasion of CRC cells was assessed by the modified Boyden’s chamber assay in 24-well cell culture plate with 8-μm pore.

Cell adhesion and cell spreading assays

Adhesion and spreading assays were performed with some modifications [15]. The 96-well plates were incubated with 2.5 μg fibronectin (Invitrogen) or 1 μg type I collagen. After treatment, tumour cells were added to each well and allowed to attach for 1 hr. Non-adherent cells were removed with PBS gently and adherent cells were stained with crystal violet. Spreading cells were identified as those cells that had distinguishable cytoplasm.

Cell proliferation, live/dead and apoptosis assays

As previously reported [16], the effect of YH-306 on CRC cell proliferation was determined by MTS assay. LIVE/DEAD® Viability/Cytotoxicity kit (Invitrogen) was utilized to assess the cell death objectively by specified the protocol. Apoptosis of CRC cells induced by YH-306 was measured by annexin V-FITC/Propidium Iodide (PI, BD Biosciences) dual staining assay.

Colony formation assay

The ability of isolated single cells to form colonies was tested using both two dimensional (2D) and 3D culture as described previously [17]. All cells were stained with crystal violet. Experiments were set up in triplicate and medium was changed twice a week.

Immunofluorescence

Immunofluorescence assays were performed according to the method previously described [18]. The YH-306-treated cells were incubated with primary antibody overnight at 4°C, followed by incubation with secondary antibodies. A laser scanning confocal imaging system (Leica, Heidelberg, Germany) was used to observe stained cells.

Animal models for tumour growth and metastasis

As previously reported [19], for tumour xenografts, 2 × 10⁶ HT-29 cells were injected into nude mice subcutaneously and the mice were treated consecutively for 20 days, with the measurement of bodyweight and the tumour dimensions. For metastasis, BALB/c mice were used. CT-26-luciferase (CT-26-luc) colon cancer cells were harvested and re-suspended. Hepatic metastases were generated by intrasplenic injection of 2.5 × 10⁶ of cancer cells and splenectomy. Pulmonary metastases were generated by tail vein injection of 2.5 × 10⁶ of cancer cells. Mice were killed after 2 weeks. All mice were intraperitoneally injected with YH-306 (20 and 50 mg/kg) every day, with an equivalent volume of dimethyl sulfoxide (DMSO) was injected in control animals (n = 5).
Immunohistochemistry

Paraffin-embedded tissues were sectioned at 5 µm, haematoxylin and eosin staining was performed according to a standard protocol. Images were taken using a Leica microscope (DM4000B; Leica). The results were analysed with Image-Pro Plus 6.0 software.

In vitro actin polymerization assay

This assay was performed as described [11] with some modifications. In brief, purified pyrene-labelled actin was re-suspended and incubated in general actin buffer for 1 hr on ice to depolymerize any actin oligomers, followed by micro-centrifugation at 4°C for 30 min. Exactly, 2 µM of actin alone or 2 µM of actin, 13 nM of Arp2/3 complexes and 100 nM of WASP protein VCA domain were incubated with DMSO (control) or 50 µM YH-306 for 15 min. on ice before pyrene actin fluorescence was measured over time.

Western blot analysis

After the treatment of YH-306, cells were harvested and lysed in radio immunoprecipitation assay buffer containing protease/phosphatase inhibitors (Roche). Lysates were combined with sample loading buffer and heated at 100°C for 10 min. Protein samples were eluted in sample buffer and subjected to SDS-PAGE.

Measurement of YH-306 binding to Arp2/3 using biolayer interferometry

Protein–small molecules interactions were examined with an Octet QK (FortéBio, Shanghai, China) by biolayer interferometry as described in previous studies [20–23]. In brief, Arp2/3 protein complex was PEG-biotinylated with NHS-PEG4biotin (Thermo-Pierce), and buffer exchanged on PD-10 desalting columns. Then, biotinylated Arp2/3 protein complex was immobilized on streptavidin-coated fibre optic tips.
YH-306 or CK-636, the positive control, was diluted into optimized binding buffer [25 mM Na HEPES (pH 8.0), 50 mM arginine-glutamate, and 150 mM NaCl].

**Statistical analysis**

Results were statistically analysed using the Student’s t-test with Microsoft Excel, and all experiments were repeated at least three times. A value of $P < 0.05$ was considered significant.

**Results**

**YH-306 suppresses the migration and invasion of CRC cells**

Migration is a key step during tumour metastasis, which is the critical reason for treatment failure and poor prognosis in patients with CRC [24]. YH-306 was identified as a new inhibitor of CRC cell migration via screening more than 70 analogues. As shown in Figure 1B, YH-306 significantly inhibited the migration of two human CRC cell lines (HCT116 and HT-29) and one mouse CRC cell line (CT-26) in a wound healing migration assay. To confirm the effect of YH-306 on migration, a transwell migration assay was performed and we found that migration of CT-26 cells was significantly reduced in a dose-dependent manner after treatment of YH-306, as shown in Figure 1C. During metastasis, cancer cells need to pass through the basement membrane, and invade surrounding tissues to infiltrate distant organs [5]. To assess the effect of YH-306 on this process, we used type I collagen and Matrigel as substrates. As shown in Figure 1D, YH-306 evidently prevented CT-26 cells from invading the type I collagen- or Matrigel-coated membrane in a dose-dependent manner.

**YH-306 inhibits adhesion and spreading of CRC cells**

Cancer cell adhesion and cell spreading based on ECM components such as type I collagen or fibronectin are required for movement of metastatic cancer into new sites. Suppression of adhesion and spreading of CRC cells is therefore considered as a promising strategy for metastastic cancer therapy [15]. To determine whether YH-306 inhibit CRC cell adhesion, we treated HCT116 and HT-29 seeded onto type I collagen or fibronectin with various concentrations of YH-306. As shown in Figure 2A, 50 μM YH-306 significantly reduced HCT116 and HT-29 adhesion onto type I collagen or fibronectin. Quantitative data revealed that 50 μM YH-306 inhibited 67% of HCT116 cell and 78% of HT-29 cell attachment to type I collagen, and attachment to fibronectin was also significantly reduced by YH-306. These results showed that YH-306 significantly inhibited HCT116 and HT-29 cells attachment to type I collagen or fibronectin in a dose-dependent manner. Furthermore, we tested the effect of YH-306 on cell spreading, and results in Figure 2B showed that YH-306 significantly suppressed cell spreading on type I collagen or fibronectin in a dose-dependent manner. Cells treated with YH-306 retained a rounded morphology (Fig. 2B) and had defects in polarized extension (Fig. 2C).

**YH-306 inhibits CRC cell growth and induces apoptosis**

MTS assays were used to test the effect of YH-306 on the proliferation of CRC cells. As shown in Figure 3A, YH-306 inhibited the growth of HCT8, HT-29, HCT116, SW480, SW620 and CT-26 cells in a dose-dependent manner after 48 hrs treatment. Fluorescence-activated cell sorting analyses in Figure 3B revealed that 50 μM YH-306 increased apoptosis of HCT116, CT-26, HT-29 and SW620 cells by sevenfold, 5.2-fold, 3.6-fold and 3.4-fold respectively, compared with untreated cells. The percentage of live (Calcein AM positive) HCT116 cells decreased from 89.9% in control groups to 56.3% in 50 μM YH-306-treated groups and that decreased to only 23.3% in 50 μM YH-306-treated SW480 cells (Fig. 3C). In addition, the percentage of Calcein AM-positive cells was reduced by YH-306 in a dose-dependent manner. Overexpression of c-myc is associated with the progression of CRC [25]. YH-306 inhibited the expression of c-myc and Bcl-xl (Fig. 3D), which is highly expressed in CRC and is correlated with prognosis of CRC [26]. In contrast, YH-306 induced the expression of the pro-apoptotic protein Bax. These results suggested that YH-306 suppressed proliferation and induced apoptosis of CRC cells. Furthermore, to examine whether YH-306 also target other cancer cells, we carried out MTS assay to test the effect of YH-306 on prostate cancer cell LNCaP and breast cancer cell MDA-MB-231, and the results shown in Figure S1 displayed that YH-306 also inhibited cell growth of prostate cancer and breast cancer.

**YH-306 suppresses colony formation and xenograft tumour growth**

The colony formation assay measures anchorage independent growth, and is considered the most stringent assay for mimicking the tumour growth in vivo. We first tested the effect of YH-306 on the 2D colony formation of HCT116 cells. As shown in Figure 4A, the number of colonies in experimental groups treated by YH-306 at 10, 20 and 50 μM only was 56.7%, 7.5% and 6.9%, respectively, of the number of colonies formed by untreated groups. HT-29 cells generated results analogous to that of HCT116 cells. In 3D colony formation assays, YH-306 also inhibited colony formation of HCT116 cells significantly compared with the untreated controls (Fig. 4B). Meanwhile, the size of the colonies formed in YH-306-treated groups is much smaller than that in untreated groups. To test the effect of YH-306 on the growth of CRC in vivo, we performed tumour xenograft assays. After administration of 20 and
50 mg/kg/day YH-306 for 20 days, as shown in Figure 4C, the average tumour volumes were 544.54 ± 32.15 mm³ (20 mg/kg/day) or 377.41 ± 44.13 mm³ (50 mg/kg/day), whereas that of untreated groups was 950.66 ± 34.30 mm³. In addition, the average tumour weight in untreated groups was 0.73 ± 0.11 g, and that in 20 or 50 mg/kg/day YH-306 groups was 0.50 ± 0.05 g or 0.34 ± 0.05 g respectively. However, the bodyweight of the mice treated with YH-306 had no obvious changes (Fig. 4C). Furthermore, we noticed that the expression of c-myc was reduced in YH-306-treated groups (Fig. 4D). In contrast, cleaved caspase3 expression was up-regulated in YH-306-treated groups (Fig. 4D). All together, the above results implied that YH-306 suppressed primary tumour growth through inhibition of proliferation and induction of apoptosis.

**YH-306 reduces hepatic metastasis of CRC**

Metastasis to distant organs is an ominous characteristic of cancer, and 80% of CRC patients with recurrent diseases develop hepatic metastasis [5]. To examine YH-306 as a potential agent against hepatic metastasis, CT-26 cancer cells exogenously expressing luciferase (CT-26-luci) were injected into the spleen and mice were treated by...
two different dosages of YH-306 (20 and 50 mg/kg) or vehicle control every day. After treatment for 14 days, as shown in Figure 5A, bioluminescence graphs showed that CT-26-luci cells largely localized in the abdomen region in untreated mice, and treatment of 50 mg/kg/day YH-306 significantly suppressed the metastasis with photon flux reduced by 77.02%. Then the mice were killed, and we found that tumour was not only localized in the liver but also spread to the intestines mesentery. To confirm the effect of YH-306 on hepatic metastasis, the liver was taken out and bioluminescence was examined. As shown in Figure 5B, 50 mg/kg/day YH-306 treatment significantly suppressed hepatic metastasis with photon flux reduced by 67.60%. Furthermore, we counted the tumour nodules per liver, compared with the untreated group, and found that the number of tumour nodules in livers from mice treated by 20 and 50 mg/kg/day YH-306 was reduced by 14.39% and 65.31%, respectively (Fig. 5C). Meanwhile, there was no obvious change in weight, or disruption in kidney or lung morphology in YH-306-treated mice (Fig. 5D). These results suggested that YH306 inhibited hepatic metastasis of CRC in vivo with no significant side effects.

**YH-306 reduces pulmonary metastasis of CRC**

To evaluate the effect of YH-306 on pulmonary metastasis, which is one cause of fatality in patients with CRC [27], we used the pulmonary metastasis model based on tail vein injection. As shown in
Figure 6A and Figure 6B, after treatment for 14 days, 20 mg/kg/day YH-306 showed no significant inhibitory effect on pulmonary metastases of CT-26-luci cells, 50 mg/kg/day YH-306 obviously inhibited pulmonary metastasis by 78.93%, compared with untreated controls. To confirm this result, the lungs were dissected from mice treated with YH-306 or vehicle control. YH-306 suppressed the number of tumour nodules in lung with significance (Fig. 6C and D). We noticed that the liver is also a metastatic target organ after tail vein injection. As shown in Figure 6E, colorectal tumour cells colonized the liver in 60% of untreated mice, whereas liver metastasis frequency was reduced to 40% and 20% respectively after administration of 20 and 50 mg/kg/day YH-306. These results indicated that YH-306 inhibited lung metastasis.

**YH-306 suppresses the activation of proteins in the FAK pathway**

Focal adhesion formation plays an important role in cell motility [28]. To understand the mechanisms involved in the suppressive effect of YH-306 on cell motility, we detected the effect of YH-306 on the distribution of F-actin and paxillin which are major components of focal...
adhesion. As shown in Figure 7A upper panel, F-actin and paxillin were mainly localized in extended cell protrusions initially contacting with ECM. In contrast, after YH-306 treatment, cells retained a round morphology without the formation of protrusions and paxillin were distributed dispersedly, which is consistent with the results above (Fig. 2C). FAK is a critical mediator in regulating cell motility including cell adhesion, spreading, migration and invasion, we found that the phosphorylation of FAK and paxillin was significantly reduced by YH-306 for 60 min. in cells exposed to fibronectin (Fig. 7A).

To further clarify the mechanism that underlies the inhibitory effect of YH-306 on CRC cells, we measured activation of several proteins involved in FAK pathway using Western blot. As shown in Figure 7C and D, after HT-29 and CT-26 cells were exposed to 50 μM YH-306 for 24 hrs, YH-306 significantly reduced the phosphorylation of FAK at Tyr397. We also performed experiments to determine whether YH-306 could act a direct inhibitor of FAK kinase activity in vitro, and found that YH-306 did not show significant inhibitory effect on FAK kinase activity in vitro compared to staurosporine as shown in Figure S2A and B. In HT-29 cells, as shown in Figure 7C, the phosphorylation of proteins involved in the FAK pathway, including c-Src, paxillin and PI3K, was significantly reduced by 50 μM YH-306. The decreased phosphorylation of PI3K was also found in CT-26 cells treated by 50 μM YH-306 (Fig. 7D). Activation of Rac1 is a vital component in FAK pathway regulating cell motility [29], and

Fig. 5 YH-306 reduces hepatic metastasis of colorectal cancer. (A) CT-26-luci cells were injected into the spleen of BALB/c mice. Representative images were taken at the 7th, 10th and 14th day respectively (left panel). Quantification of metastatic cells in whole body was determined by bioluminescence analysis (right panel). (B) Colorectal cancer cell metastases in liver and quantitative data of metastatic cells only in liver. (C) Upper panel, observational analyses of colorectal cancer metastases in livers from mice treated by YH-306 or DMSO. Lower panel, the cancer metastatic nodules on the liver surface were counted from mice. (D) The body-weight of mice was measured. The kidney and lungs were excised from indicated mice, then fixed in 4% paraformaldehyde and stained with haematoxylin and eosin. *P < 0.05; **P < 0.01; ***P < 0.001.
pull down assays revealed that YH-306 inhibited the activation of Rac1 GTPase in HT-29 cells (Fig. 7E). To examine the individual importance of Src, PI3K and Rac1 for survival, adhesion and migration of CRC cell, we used Src inhibitor PP1, PI3K inhibitor LY294002 and Rac1 inhibitor NSC23766. The data shown in Figure S3 suggested that YH-306 suppressed cell growth, adhesion and migration of CRC cell through Src, PI3K and Rac1, but not depending on them.

It is reported that MMPs play an important role in the cancer metastatic cascade [30], and the expression of MMP2 and MMP9 is induced by FAK [31]. In this study, we found that 50 μM YH-306 strongly reduced MMP2 and MMP9 expression in HT-29 cells. To confirm this effect of YH-306, we then measured the expression of TIMP1 and found that YH-306 up-regulated the expression of TIMP1 in a dose-dependent manner (Fig. 7C). Meanwhile, in CT-26 cells,
50 μM YH-306 also showed significantly inhibitory effect on the expression of MMP2 and MMP9 as well as the phosphorylation of Erk (Fig. 7D).

**YH-306 suppresses the distribution of Arp3 and inhibits Arp2/3 complex-mediated actin polymerization**

The Arp2/3 complex drives many types of cell movement such as protrusion formation, cell spreading and actin polymerization [11, 32]. To examine the effect of YH-306 on the Arp2/3 complex, we examined the recruitment of Arp3. The recruitment of Arp3 to the protrusions of cells treated with YH-306 was reduced compared with untreated cells (Fig. 7B). The cell morphology in Figure 7A and B showed some defects in the cytoskeleton of cells treated with YH-306. In HT-29 and CT-26 cells, the expression of Arp3 did not show a significant change (Fig. 7C and D), suggesting that YH306 inhibited the recruitment but not the expression of Arp3. To confirm whether this morphology result from the inhibition of Arp2/3 complex-regulated actin polymerization which is required for dynamic morphological changes [33], we performed Arp2/3 complex-regulated actin polymerization assays in vitro. As shown in Figure 7B lower panel, YH-306 inhibited Arp2/3 complex-regulated actin polymerization at 10 min. [11]. To further determine whether YH-306 could acts an ATP analogue and disturb ATP-dependent actin polymerization on its own, we perform ATP-dependent actin polymerization assay in which Arp2/3 complex and N-Wasp protein were not included. The result
was shown in Figure S2C, suggesting that YH-306 did not show significant inhibitory effect on ATP-dependent actin polymerization at 10 min.

**Discussion**

In this study, we demonstrated that a novel synthetic small molecule, YH-306, inhibited colorectal tumour growth and hepatic/pulmonary metastasis. The inhibitory effect of YH-306 resulted from the suppression of proliferation and motility. The potential mechanism by which YH-306 affected CRC may be because of inhibition of FAK and Arp2/3 pathway.

Liver and/or lungs are the typical sites of CRC metastases and hepatic/pulmonary metastasis account for the lethality in patients with CRC [5, 27, 34]. So, effective anti-metastasis drugs for malignant CRC treatment are urgently needed. YH-306 prevented CRC cells from invading the liver after intrasplenic injection. Besides in the liver, colorectal tumours were also observed in the intestines mesentery (data not shown). Our data suggested that YH-306 also inhibited the localization of CRC to the intestines mesentery. Compared with the liver, the lungs are the second most frequently target organ of CRC [5]. YH-306 inhibited lung metastasis of CRC cells, and suppressed the liver metastasis caused by tail vein injection of CRC cells (Figs 5 and 6). In addition to the inhibition of CRC metastasis, YH-306 also inhibited colorectal tumour growth by inhibiting CRC proliferation and inducing cell apoptosis (Figs 3 and 4). These results suggested that YH-306 inhibited the progression of CRC in vivo.

Migration is necessary for malignant cancer cells to invade adjacent tissues and metastasize to distant organs [35], and suppressing the initiation of migration is a promising approach to inhibit cancer cell dissemination [36]. The process of migration underlies the invasion of cancer cells, and intravital microscopy studies displayed that cancer cells switch invasion strategies in response to ECM resulting in intravasation into blood vessels [37]. YH-306 showed a significantly inhibitory effect on the migration and invasion of CRC cells in a dose-dependent manner (Fig. 1). We also found that YH-306 was more effective at inhibiting migration and invasion than proliferation in CRC cells under the same concentrations and time (data not shown).

The process by which cancer cells attach to the vessel wall in distant organs and migrate out of the vessel is considered another crucial step of cancer metastasis [38]. During this process, to interact with neighbouring cells and ECM, cell–cell and cell–ECM adhesions are formed [39], and cell protrusion and polarity is also important for invasive tumours [6, 40]. After YH-306 treatment, CRC cells HCT116 and HT-29 were prevented from attachment, and remained rounded without polarity as well as failed to form protrusions at the leading edge in response to type I collagen or fibronectin stimuli (Fig. 2). Consistent with these results, YH-306 treatment resulted in the reduction in filament-based cell–ECM contacts localized at cell adhesions and a random distribution of paxillin at the peripheral sites (Fig. 7A, upper panel). These data implied that YH-306 inhibited migration and invasion resulting from interfering with initial processes in the metastatic cascade, which leads to the suppression of metastasis.

Cell migration is a highly integrated multistage process that is initiated by the protrusion of the cell membrane and focal adhesions [41, 42]. FAK and Arp2/3 are important factors during cell migration. FAK is correlated with the prognosis and clinicopathological parameters of some human malignancies, including CRC [43, 44]. Arp2/3 controls network of actin filaments and drives membrane protrusion during migration. Importantly, FAK and Arp2/3 complex associate and colocalize at transient structures formed early after adhesion during the cell migration [11]. On the other hand, FAK/Pi3K/Rac1 signalling also plays an important role in several kinds of cancer including breast cancer and CRC [45, 46]. Localization of FAK into adhesions induces its phosphorylation at Tyr397 and subsequently phosphorylation of c-Src and paxillin which also play an important role in focal adhesions [10, 47, 48]. Phosphorylated Pi3K induces the activation of Rac1 [49]. Rac1 activity induces the recruitment of Arp2/3 complexes [42], which is considered as a potential risk factor for liver metastasis of CRC [50, 51]. FAK also induces the expression of MMP2 and MMP9 accounting for cancer invasion and metastasis via ERK or JNK pathways [31, 52, 53]. The effect of YH-306 on the ERK phosphorylation was weak, implying that YH-306 inhibited MMP2 and MMP9 expression via JNK pathway probably. In this study, YH-306 inhibited FAK/Pi3K/Rac1 pathway activation and the recruitment of Arp3 as well as the expression of MMP2 and MMP9, resulting in the suppression of CRC metastasis. In addition, as shown in Figure 7B, YH-306 suppressed the Arp2/3 complex-mediated actin polymerization which plays an important role in cell migration and invasion. Unlike the small molecule, CK636, used as a positive control compound, directly bound to Arp2/3 to block movement of Arp2 and Arp3 into their active conformation in the polymerization of actin (data not shown), which was consistent with previous reports [32, 54]. YH-306 did not bind to the Arp2/3 complex directly (data not shown), suggesting that YH-306 inhibited Arp2/3 complex-regulated actin polymerization via other means.

Collectively, in this study, we provided evidence that YH-306 inhibited CRC cell migration, invasion and proliferation in vitro resulting in the suppression of growth and metastasis in vivo via inhibition of the FAK pathways, implying that YH-306 might be valuable in preventing CRC growth and metastasis.

**Acknowledgements**

This study was partially supported by Major State Basic Research Development Program of China (2012CB910400, 2009CB918402), National Natural Science Foundation of China (81272463, 81071807, 81742788, 81330049), Program for Changjiang Scholars and Innovative Research Team in University (IRT1128), Innovation Program of Shanghai Municipal Education Commission (13zz034). The Science and Technology Commission of Shanghai Municipality (11022260300, 12XDA1406100), Research Fund for the Doctoral Program of Higher Education of China (2012078120029). We thank Dr. Stefan Siwko at Texas A&M University Health Science Center for his comments and editing.
Conflicts of interest

The authors declare that they have no competing interests.

Supporting information

Additional Supporting Information may be found in the online version of this article:

References

1. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1839–907.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11–30.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.
4. Jin K, Gao W, Lu Y, et al. Mechanisms regulating colorectal cancer cell metastasis into liver (Review). Oncol Lett. 2012; 3: 11–5.
5. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9: 274–84.
6. Wozniak MA, Modzelewksa K, Kwong L, et al. Focal adhesion regulation of cell behavior. Biochim Biophys Acta. 2004; 1692: 103–19.
7. Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004; 6: 54–61.
8. Chen HC, Appedu PA, Isoda H, et al. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidyl-inositol 3-kinase. J Biol Chem. 1996; 271: 26329–34.
9. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011; 63: 610–5.
10. Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004; 14: 241–9.
11. Serrels B, Serrels A, Brunton VG, et al. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol. 2007; 9: 1046–56.
12. Ortar G, De Petrocellis L, Moriello AS, et al. Tetrahydro-beta-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. Bioorg Med Chem Lett. 2013; 23: 138–42.
13. Zheng C, Fang Y, Tong W, et al. Synthesis and biological evaluation of novel tetrahydro-beta-carboline derivatives as anti-tumor growth and metastasis agents through inhibiting the transforming growth factor-beta signaling pathway. J Med Chem. 2014; 57: 600–12.
14. Dai F, Chen Y, Song Y, et al. A natural small molecule harmine inhibits angiogenesis and suppresses tumor growth through activation of p53 in endothelial cells. PLoS ONE. 2012; 7: e52102.
15. Huang Q, Shen HM, Shui G, et al. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res. 2006; 66: 5807–15.
16. Song Y, Dai F, Zhai D, et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis. 2012; 15: 421–32.
17. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 2005; 65: 5356–64.
18. Zhang T, Li J, Dong Y, et al. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat. 2012; 135: 445–58.
19. Lai L, Liu J, Zhai D, et al. Plumbagin inhibits its tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br J Pharmacol. 2012; 165: 1084–96.
20. Landgraf KE, Santell L, Billeci KL, et al. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling. J Biol Chem. 2010; 285: 40362–72.
21. Lin YP, Xiong X, Wharton SA, et al. Evaluation of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci USA. 2012; 109: 21474–9.
22. Landgraf KE, Santell L, Billeci KL, et al. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling. J Biol Chem. 2010; 285: 40362–72.
23. Lin YP, Xiong X, Wharton SA, et al. Evaluation of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci USA. 2012; 109: 21474–9.
24. Zhang YY, Chen B, Ding YQ. Metastasis-associated factors facilitating the progression of colorectal cancer. Asian Pac J Cancer Prev. 2012; 13: 2437–44.
25. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281: 1509–12.
26. Yang J, Sun M, Zhang A, et al. Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells. World J Surg Oncol. 2011; 9: 117.
27. Davidson RS, Nwogu CE, Brentjens MJ, et al. The surgical management of pulmonary metastasis: current concepts. Surg Oncol. 2001; 10: 35–42.
28. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6: 56–68.
29. Park SJ, Jeon YJ. Dieckol from Ecklonia cava suppresses the migration and invasion of HT1080 cells by inhibiting the focal adhesion kinase pathway downstream of Rac1-Rho signaling. Mol Cells. 2012; 33: 141–9.
30. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295: 2387–92.
31. McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 2005; 5: 505–15.
32. Nolen BJ, Tomasevic N, Russell A, et al. Characterization of two classes of small mol-
ecule inhibitors of Arp2/3 complex. Nature. 2009; 460: 1031–4.

33. Ten Klooster JP, Evers EE, Janssen L, et al. Interaction between Tiam1 and the Arp2/3 complex links activation of Rac to actin polymerization. Biochem J. 2006; 397: 39–45.

34. Lassmann S, Tang L, Capanu M, et al. Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. Gastroenterology. 2007; 133: 1831–9.

35. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 2007; 1773: 642–52.

36. Aman A, Piotrowski T. Cell migration during morphogenesis. Dev Biol. 2010; 341: 20–33.

37. Beerling E, Ritsma L, Vrisekoop N, et al. Intravitral microscopy: new insights into metastasis of tumors. J Cell Sci. 2011; 124: 299–310.

38. van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011; 728: 23–34.

39. Kawachi T. Cell adhesion and its endocytic regulation in cell migration during neural development and cancer metastasis. Int J Mol Sci. 2012; 13: 4564–90.

40. Etienne-Manneville S. Polarity proteins in migration and invasion. Oncogene. 2008; 27: 6970–80.

41. Bailly M, Condeelis J. Cell motility: insights from the backstage. Nat Cell Biol. 2002; 4: E92–4.

42. DeMali KA, Barlow CA, Burridge K. Recruitment of the Arp2/3 complex to vinculin: coupling membrane protrusion to matrix adhesion. J Cell Biol. 2002; 159: 881–91.

43. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci. 2010; 123: 1007–13.

44. Chatzizacharias NA, Kouraklis GP, Theocaris SE. Clinical significance of FAK expression in human neoplasia. Histol Histopathol. 2008; 23: 629–50.

45. Kallergi G, Agelaki S, Markomanolaki H, et al. Activation of FAK/Pi3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Cell Physiol Biochem. 2007; 20: 977–86.

46. Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J. 2007; 21: 1730–41.

47. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004; 4: 470–80.

48. Kwong L, Wozniak MA, Collins AS, et al. R-Ras promotes focal adhesion formation through focal adhesion kinase and p130 (Cas) by a novel mechanism that differs from integrins. Mol Cell Biol. 2003; 23: 933–49.

49. Chang F, Lemmon CA, Park D, et al. FAK potentiates Rac1 activation and localization to matrix adhesion sites: a role for betaPIX. Mol Biol Cell. 2007; 18: 253–64.

50. Iwaya K, Oikawa K, Semb S, et al. Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma. Cancer Sci. 2007; 98: 992–9.

51. Otsubo T, Iwaya K, Mukai Y, et al. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Mod Pathol. 2004; 17: 461–7.

52. Shih YW, Chien ST, Chen PS, et al. Alpha-mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via alphavbeta3 integrin/FAK/ERK and NF-kappaB signaling pathway in human lung adenocarcinoma A549 cells. Cell Biochem Biophys. 2010; 58: 31–44.

53. Van Slambrout S, Grijelmo C, De Wever O, et al. Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int J Oncol. 2007; 31: 1501–8.

54. To C, Shilton BH, Di Guglielmo GM. Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization. J Biol Chem. 2010; 285: 27944–57.